FibroGen Inc (NASDAQ:FGEN)’s share price traded down 1.4% during trading on Monday after an insider sold shares in the company. The stock traded as low as $33.51 and last traded at $35.88. 54,019 shares changed hands during trading, a decline of 91% from the average session volume of 624,578 shares. The stock had previously closed at $36.39.
Specifically, SVP Christine Chung sold 11,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $46.41, for a total value of $522,112.50. Following the sale, the senior vice president now owns 163,562 shares of the company’s stock, valued at $7,590,912.42. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction that occurred on Wednesday, February 20th. The shares were sold at an average price of $57.41, for a total transaction of $2,275,502.76. Following the completion of the sale, the chief executive officer now directly owns 2,658,056 shares in the company, valued at approximately $152,598,994.96. The disclosure for this sale can be found here. In the last three months, insiders sold 231,791 shares of company stock worth $12,644,356. Insiders own 8.96% of the company’s stock.
FGEN has been the subject of several recent analyst reports. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 22nd. ValuEngine cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 14th. Stifel Nicolaus initiated coverage on shares of FibroGen in a research note on Monday, February 11th. They set a “buy” rating and a $71.00 price objective for the company. Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research note on Friday, March 8th. Finally, TheStreet raised shares of FibroGen from a “d+” rating to a “c-” rating in a research note on Friday, March 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. FibroGen currently has a consensus rating of “Buy” and an average price target of $68.50.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.15. FibroGen had a negative net margin of 44.14% and a negative return on equity of 17.69%. The business had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $20.44 million. During the same quarter in the previous year, the company earned ($0.50) EPS. The business’s quarterly revenue was down 25.1% compared to the same quarter last year. Analysts anticipate that FibroGen Inc will post -0.97 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in the business. Trexquant Investment LP purchased a new position in FibroGen in the 1st quarter worth approximately $913,000. Northern Trust Corp grew its stake in FibroGen by 2.0% in the 1st quarter. Northern Trust Corp now owns 937,831 shares of the biopharmaceutical company’s stock worth $50,972,000 after buying an additional 18,745 shares in the last quarter. WCM Investment Management LLC purchased a new position in FibroGen in the 1st quarter worth approximately $497,000. Dynamic Technology Lab Private Ltd purchased a new position in FibroGen in the 1st quarter worth approximately $254,000. Finally, State of Wisconsin Investment Board grew its stake in FibroGen by 36.5% in the 1st quarter. State of Wisconsin Investment Board now owns 105,400 shares of the biopharmaceutical company’s stock worth $5,728,000 after buying an additional 28,200 shares in the last quarter. 66.67% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “FibroGen (FGEN) Stock Price Down 1.4% After Insider Selling” was published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/14/fibrogen-fgen-stock-price-down-1-4-after-insider-selling.html.
FibroGen Company Profile (NASDAQ:FGEN)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also: Understanding Market Liquidity
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.